Search the Newsreel

Prestige Consumer Healthcare (PBH) Bets Big On M&A, But Can Clear Eyes Recover?

Prestige Consumer Healthcare (NYSE:PBH) closed two acquisitions within three weeks this summer, adding roughly $240 million in annualized revenue to a portfolio anchored by Dramamine and Compound W. The first quarter fiscal 2027 earnings call, held August 6, showed a company beating its own …

Prestige Consumer Healthcare (NYSE:PBH) Upgraded by Zacks Research to "Hold" Rating

Zacks Research has upgraded Prestige Consumer Healthcare (NYSE:PBH) from a "strong sell" to a "hold" rating. This upgrade comes after the company exceeded quarterly earnings expectations, reporting $0.98 EPS against a $0.89 consensus and revenue of $265.71 million, a 6.5% increase year-over-year. The consensus …

Renaissance Technologies LLC Has $2.17 Million Stake in Prestige Consumer Healthcare Inc. $PBH

Renaissance Technologies LLC significantly reduced its stake in Prestige Consumer Healthcare Inc. (PBH) by 62% in the first quarter, selling 59,900 shares but retaining 36,702 shares valued at approximately $2.17 million. Despite this, institutional investors collectively own 99.95% of PBH. Prestige Consumer Healthcare reported …

Quantinno Capital Management LP Acquires 19,281 Shares of Prestige Consumer Healthcare Inc. $PBH

Quantinno Capital Management LP significantly increased its stake in Prestige Consumer Healthcare Inc. (PBH) by acquiring 19,281 shares, bringing its total holdings to 36,990 shares valued at $2.19 million. Institutional investors collectively own 99.95% of PBH. The company also surpassed quarterly earnings expectations, reporting …

Prestige Consumer Healthcare (PBH) Is Up 5.6% After Raising Fiscal 2027 Outlook on Acquisitions

Prestige Consumer Healthcare (PBH) saw its stock rise by 5.6% after reporting its fiscal 2027 first-quarter results and subsequently raising its full-year outlook. The company's updated revenue guidance of US$1.29 billion–US$1.32 billion and GAAP diluted EPS guidance of US$4.18–US$4.28 are primarily driven by recent …

Prestige Consumer Executives Set for Aug. 12 Fireside Chat

Prestige Consumer Healthcare Inc. (NYSE: PBH) announced that its CFO and COO, Christine Sacco, and VP of Investor Relations, Treasury, & Business Development, Phil Terpolilli, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026, at …

Prestige Consumer Healthcare Inc. to Participate in Canaccord Genuity Annual Growth Conference

Prestige Consumer Healthcare Inc. announced that its CFO and COO, Christine Sacco, and VP of Investor Relations, Treasury, & Business Development, Phil Terpolilli, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference. The event is scheduled for Wednesday, August …

Prestige Consumer Healthcare (PBH) Following Its 2027 Outlook Raise And The Undervalued View

Prestige Consumer Healthcare (PBH) has raised its fiscal 2027 revenue and earnings outlook, projecting revenue between $1.29b and $1.32b and GAAP diluted EPS between $4.18 and $4.28, driven by the integration of two recent acquisitions. Despite a mixed share price performance over the past …

Read This Before Considering Prestige Estates Projects Limited (NSE:PRESTIGE) For Its Upcoming ₹2.00 Dividend

Prestige Consumer Healthcare (PBH) Stock Faces Margin Questions Despite Record Cash Flow

Prestige Consumer Healthcare (PBH) Is Up 9.2% After Raising 2027 Outlook On Recent Acquisitions

In early August 2026, Prestige Consumer Healthcare reported fiscal 2027 first‑quarter revenue of US$265.71 million, up from US$249.53 million a year earlier, and raised its full‑year 2027 revenue outlook to US$1.29 billion–US$1.32 billion and projected GAAP diluted EPS of US$4.18–US$4.28, reflecting the addition of …

Prestige Consumer Healthcare Inc. $PBH Shares Bought by First Trust Advisors LP

First Trust Advisors LP significantly increased its stake in Prestige Consumer Healthcare Inc. (PBH) by 137.5% in the first quarter, now owning 37,395 shares valued at approximately $2.2 million. The company exceeded quarterly expectations with adjusted EPS of $0.98 and revenue of $265.7 million, …

Prestige Consumer Healthcare Inc (PBH) (Q1 2027) Earnings Call Highlights: Record Cash Flow and ...

Prestige Consumer Healthcare Inc. (PBH) reported exceeding sales and earnings expectations in Q1 fiscal 2027, with total sales up 6.5% to $266 million and record adjusted free cash flow of $83.7 million. The company successfully integrated the Breathe Right acquisition and completed another strategic …

Prestige Consumer Healthcare Stock (PBH) Opinions on Recent Earnings and M&A Activity

Breathe Right and LaCorium Acquisitions Raise Prestige Consumer's 2027 Outlook

Prestige Consumer Healthcare reported strong Q1 fiscal 2027 results with revenue up 6.5% to $265.7 million and adjusted diluted EPS rising to $0.98. The company's recent acquisitions of Breathe Right and LaCorium Health significantly contributed to these results and led to a raised fiscal …

Prestige Consumer Healthcare Inc. 2026: Revenue $265.71M, EPS $0.61— 10-Q Summary

Prestige Consumer Healthcare Inc. reported a Q2 2026 revenue increase to $265.71M, up 6.5% year-over-year, driven by growth in both North America and International markets. Despite revenue growth, net income and diluted EPS declined by 38.5% and 35.8% respectively compared to the prior-year quarter. …

Prestige Consumer Healthcare (NYSE: PBH) expands with $1,045.0M wellness deal

Prestige Consumer Healthcare Inc. (NYSE: PBH) reported its Q1 2027 earnings, revealing a 6.5% increase in total revenues to $265.7 million for the quarter ended June 30, 2026, primarily driven by the $1,045.0 million acquisition of the OTC Wellness Business, including the Breathe Right …

Earnings call transcript: Prestige Consumer beats Q1 2026 estimates as stock edges higher

Prestige Consumer Healthcare reported stronger-than-expected Q1 fiscal 2027 results, with adjusted EPS of $0.98 and revenue of $265.7 million, both exceeding analyst estimates. The company saw organic revenue growth of 3.2% and a record adjusted free cash flow of $83.7 million, while integrating the …

Prestige Consumer Healthcare Inc. 2027 Q1 - Results - Earnings Call Presentation (NYSE:PBH) 2026-08-06

Prestige Consumer Healthcare Inc. (PBH) has released its Q1 2027 earnings call presentation. The company reported an EPS of $0.98, beating estimates by $0.10, and revenue of $265.71M, surpassing expectations by $15.39M, representing a 6.48% year-over-year increase. This article provides access to the slide …

Prestige Consumer Healthcare (PBH) Q1 Earnings and Revenues Surpass Estimates

Prestige Consumer Healthcare (NYSE: PBH) awards director 2,981 RSUs

Prestige Consumer Healthcare (NYSE: PBH) director Dawn M. Zier was granted 2,981 restricted stock units (RSUs) as part of the company's director compensation program. The RSUs, valued at $155,000 based on a $52.00 closing stock price, will vest on the first anniversary of the …

Earnings Flash (PBH) Prestige Consumer Healthcare Inc. Reports Q1 Revenue $265.7M, vs. FactSet Est of $250.3M

Prestige Consumer Healthcare Inc. (PBH) reported its Q1 revenue of $265.7 million, surpassing FactSet's estimate of $250.3 million. This positive earnings flash was published on August 6, 2026, and also follows an earlier report of the company raising its earnings guidance for fiscal year …

Prestige Consumer Healthcare Inc. Reports Fiscal 2027 First Quarter Results

Prestige Consumer Healthcare Inc. reported strong first-quarter fiscal 2027 results, exceeding sales and earnings expectations with a revenue of $265.7 million, up 6.5%, and organic sales growth of 3.2%. The company closed the Breathe Right® and LaCorium acquisitions, which contributed to its performance and …

Prestige Estates uploads Q1FY27 earnings call transcript for investors

Avoiding Lag: Real-Time Signals in (PBH) Movement

This article provides a real-time analysis of Prestige Consumer Healthcare Inc. (NYSE: PBH) stock movements, highlighting strong near- and mid-term positive sentiment but a weak long-term outlook. It identifies key resistance levels and offers institutional trading strategies including position, momentum breakout, and risk hedging, …

Price to sales forward of Prestige Consumer Healthcare Inc. – NYSE:PBH

This article provides financial data for Prestige Consumer Healthcare Inc. (NYSE: PBH), specifically its price-to-sales forward metric. The content appears to be a financial snapshot from a trading platform, indicating market status and general financial information for the company.

Prestige Consumer Number of Employees 2026 | Employee Count & Headcount Data

Prestige Consumer Healthcare, Inc. (PBH) had 897 employees worldwide as of March 2026, representing a 10.6% growth since 2023. The company is actively hiring, although job postings declined by 2.7% in 2026 compared to 2025. Its workforce is primarily concentrated in the United States, …

What You Need To Know About The Prestige Estates Projects Limited (NSE:PRESTIGE) Analyst Downgrade Today

PBH|Prestige Consumer Healthcare Inc|Price:52.180|Chg%:+0.460

Prestige Consumer Healthcare Inc. (PBH) shows healthy fundamentals and high growth potential, with its valuation considered fairly priced within the Pharmaceuticals industry. Institutional ownership is notably high, and analysts have consistently rated the stock as "Buy," with a target price of $66.00. Despite strong …

Prestige Consumer Healthcare Inc (PBH) Institutional Confidence

Prestige Consumer Healthcare Inc (PBH) has a strong institutional confidence score of 10.00, placing it first in the Pharmaceuticals industry. The institutional shareholding proportion has increased to 121.63%, with John Rogers being the largest institutional shareholder. Several major institutional investors hold significant shares, with …

Prestige Estates posts muted Q1 earnings; Nomura retains Buy, target price at Rs 1,900

Earnings call transcript: Prestige Estates misses q1 2026 estimates as stock falls

Prestige Estates Q1 net profit falls 19% despite 16% revenue growth; sales plunge 46%